This highflier has fallen on hard times recently. Moderna Therapeutics (MRNA -2.01%) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine. While COVID has not gone away, the virus is no longer top of mind, and fewer people feel the need to update their vaccination for the illness. With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Inv ...

Moderna held its annual R&D day this week. Moderna's (MRNA -2.01%) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand for its coronavirus vaccine waned, but seemed to be on the road to recovery. It won approval for its new respiratory syncytial virus (RSV) vaccine, reported positive data from trials of late-stage candidates, and even saw its shares climb about 20% in the first half of the year. But Moderna's news hasn't been as bri ...

Key Takeaways Shares of Moderna fell Friday after taking on steep losses a day earlier on the news that it plans to cut research and development spending by $1.1 billion by 2027. JP Morgan analysts, meanwhile lowered their rating to underperform from neutral. JP Morgan's $70 price target on the stock is substantially below Wall Street's consensus of around $100. Shares of Moderna (MRNA) fell for the second day in a row after the company said it would slash its research and development expenditures. The stoc ...

At its annual R&D Day, Moderna (MRNA) announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years. MRNA to Cut R&D Costs, Stops Five Pipeline Programs Management implemented a portfolio prioritization and cost efficiencies program to reduce annual research and development (R&D) expenses and focus on products that are either nearing approvals or already on the market. The firm reduced its overall R&D budget for the next four years (2025 to 2028) by nearly ...

These players have had their ups and downs -- but the future looks bright. Though the S&P 500 dipped earlier this month, it's important to keep in mind that we're still in a very positive market environment. The bull market is going strong, with the benchmark rising 17% so far this year. And since bull phases generally last longer than bear ones, it's possible that the good times will keep on rolling. How can you benefit? By scooping up a few players that haven't yet picked up momentum but have the potentia ...

Key Takeaways The S&P 500 added 0.8% on Thursday, Sept. 12, 2024, extending its winning streak to four days as the latest PPI data showed a softening in wholesale inflation. Warner Bros. Discovery shares surged after entertainment giant renewed its distribution deal with Charter Communications. Kroger's stock rose on earnings news. Moderna said it will cut back on research and development spending, and shares of the vaccine maker plunged. Major U.S. equities indexes headed higher after the latest Producer P ...

Shares of Moderna Inc (NASDAQ:MRNA) are plummeting today, after the biotech giant announced it was slashing its research budget by about 20%. The company also teased the launch of 10 new products before then. On the short sell restricted (SSR) list amid the volatility, MRNA was last seen down 17.8% at $65.38, hitting its lowest levels since early November. The stock has continued to move lower since its 21.1% post-earnings drop on August 1, and is currently down 35.4% year to date. Options traders are chimi ...

About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical wri ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 12, 2024 /PRNews ...

Key Takeaways Moderna shares fell Thursday morning after the COVID vaccine maker announced plans to trim its research and development pipeline to cut costs. The company said it will focus on getting FDA approval for 10 products to treat RSV and cancer, along with a combination COVID and flu vaccine. Moderna said it expects the moves to lower expenses by $1.1 billion by 2027. Moderna (MRNA) shares tumbled in pre-market trading Thursday as the company said it plans to cut costs and suspend or end development ...